Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663056 | 0.90 | HDAC1 (0.43) | HDAC1BRD4JAK1HRH3HDAC2 | |
| SCHEMBL3664966 | 0.87 | HDAC2 (0.51) | HDAC1MCHR1BRD4JAK1HDAC2 | |
| SCHEMBL3659165 | 0.86 | HDAC1 (0.46) | HDAC1BRD4JAK1HRH3HDAC2 | |
| SCHEMBL3666548 | 0.86 | HDAC1 (0.44) | HDAC1MCHR1BRD4JAK1HRH3 | |
| SCHEMBL3665075 | 0.86 | HDAC1 (0.43) | HDAC1MCHR1HDAC2HDAC3PTGS1 | |
| SCHEMBL3662770 | 0.86 | HDAC2 (0.51) | HDAC1MCHR1BRD4JAK1HDAC2 | |
| SCHEMBL3659100 | 0.86 | MCHR1 (0.43) | HDAC1MCHR1BRD4JAK1HDAC2 | |
| SCHEMBL3664631 | 0.83 | HDAC1 (0.43) | HDAC1BRD4JAK1HDAC2HDAC3 | |
| SCHEMBL3660074 | 0.81 | HDAC2 (0.46) | HDAC1BRD4JAK1HDAC2HDAC3 | |
| SCHEMBL3663180 | 0.80 | HDAC1 (0.51) | HDAC1BRD4JAK1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885MCHR1 4638/4885BRD4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.